At CD BioSciences, our commitment to advancing human herpesvirus (HHV) research is reflected in the success of our partners. The Case Studies section in our Resources hub offers a curated collection of real-world examples demonstrating how our preclinical platforms and scientific expertise have accelerated drug and vaccine development programs targeting HSV, CMV, VZV, and KSHV.
Each case study provides a concise, transparent narrative of how we support clients—from hit-to-lead optimization and mechanistic characterization to IND-enabling safety studies and immune response profiling. Whether you're a biotech startup seeking to differentiate a novel compound or a pharmaceutical company evaluating combination immunotherapies, our case studies highlight the practical applications of our platforms and the value of partnering with CD BioSciences.
Accelerating a Novel HSV-2 Helicase Inhibitor from Hit-to-Lead
IND-Enabling Safety Package for a Therapeutic CMV Vaccine Candidate
Characterizing the Immunomodulatory Effects of an Oncolytic HSV in Combination with a PD-1 Inhibitor
Differentiating a Novel VZV Antiviral Against Standard-of-Care in a Preclinical Shingles Model